Oragenics COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Oragenics Inc OGEN announced the results from its hamster challenge study to evaluate the COVID-19 vaccine candidate.

  • The study is assessing the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate.
  • The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
  • Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. 
  • By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. 
  • Related: Oragenics Launches Animal Study For COVID-19 Vaccine Candidate.
  • The Company plans to file Investigational New Drug Application to the FDA in Q2 of 2022.
  • Price Action: OGEN shares are down 0.45% at $0.57 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!